Burn at this point hardly matters. The real point is that they haven't found any way to get the drug even marginally accepted in the medical and diabetic community.
Even if they were to gain some traction with scripts, they still need some 60 million dollars cash between now and September, 2018, just to make debt payments.
Add on the 150 million burn between now and then and you're looking at needing over 200 million dollars over about 16 months. Where will it come from other than major dilution?
Market Data 
Markets 
AI
